Carrie Brodmerkel | Director of Immunology Biomarkers
Janssen

Carrie Brodmerkel, Director of Immunology Biomarkers, Janssen

Carrie Brodmerkel

Head, Immunology Biomarkers, Immunology Therapeutic Area, Janssen R&D

Carrie is currently Head of Immunology Biomarkers at Janssen R&D, part of the pharmaceutical companies of Johnson & Johnson (J&J), with responsibility for strategic and operational implementation of biomarker efforts for the Immunology Therapeutic Area.  The team is responsible end to end for biomarkers in support of assets in development for disease interception, early disease intervention and treatment of established disease in the areas of rheumatoid arthritis, inflammatory bowel disease and psoriasis.  This includes efforts in early development for pharmacodynamics assays and developing alternative endpoints for improved decision making in early phase trials.  Carrie has been with Janssen R&D since 2005 with a focus on biomarkers and in her early career focused on pre-clinical drug discovery efforts utilizing in vivo pharmacological modeling of immune diseases in her roles at Dupont Pharmaceuticals and Incyte Corporation.  Carrie earned her Ph.D. in Pathology at Albert Einstein College of Medicine studying chemokines and chemokine receptors and their role in the neuroinflammatory processes of multiple sclerosis and HIV encephalopathy and a post-doctoral fellowship at the University of Pennsylvania, studying chemokine receptors and their role in HIV entry. 

Appearances:



Microbiome World Congress USA Day 1 2017 @ 14:00

Presentation: Developments of Targeted Therapy via Microbiome Community

Commercial
  • The level of uniqueness in the microbiome make up means far more
  • How can we enhance sampling protocols with high quality metagenomic data?
  • How in depth must we go to identify key bacteria of interest?
  • With current treatments having wide ranging responses in patients- How personalized does each treatment need to be?

back to speakers